Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:21:09.669Z.
Calculation as of: 2026-10-06T17:21:09.669Z.
Quote observation: 2026-10-06T17:20:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6abed0f02887b3ac62520bc322e243c8ff06f4fcddd7c97914d2a236e2670171
PE RATIO
N/A
Market Cap
$301.57M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $321.34M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $319.78M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $321.22M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.39M | N/A | 16.56 | 19.39 | 19.39 |
| CapsoVision, Inc. (CV)vs › | $323.76M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $325.64M | 2.96 | 2.74 | 2.74 | 27.61 |
| C4 Therapeutics, Inc. (CCCC)vs › | $311.25M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $301.57M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.82M | N/A | 396.83 | 396.83 | 396.83 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.28M | N/A | 0.72 | 0.72 | 0.72 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.71
Forward EPS (Est.)
$-1.30
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
